Biogen: Numbers Are Fine But Valuation Isn't Appealing

On January 25, 2018, Biogen (NASDAQ:BIIB) reported strong Q4 2017 results, thanks to a solid performance of Tecfidera and Spinraza and an excellent Opex management.

Even if I like the R&D productivity of the company, after the strong performance in the last seven months and a 50% move off its lows, a valuation check suggests that it’s time to take profits on Biogen.

Q4/2017 results & 2018 Guidance

Biogen reported Q4 2017 sales of $3.31B, 7% ahead of consensus expectations, while Core EPS were $5,26, 3% below street numbers, driven to a lower than expected Gross Margin and a higher tax rate for some one-offs.

2018 guidance looks solid and implies some upgrades of Street numbers. Biogen guided for a Non – GAAP EPS between $24.20 and $25.20, which implies around 3% of upgrade of consensus, which was at $24 before the results.

READ FULL ARTICLE HERE